Best of ASCO - 2014 Annual Meeting

 

Welcome

Conduct of Clinical Research

Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics

2018 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
A phase I molecular adaptive clinical study to evaluate safety and tolerability of BPM31510-IV in advanced solid tumors: Final study results.

Niven R. Narain

2541

A randomized Bayesian phase 1 design combining an MPS-1 inhibitor with paclitaxel: A strategy to improve determination of the incremental toxicity of a novel compound over a known backbone therapy.

Florence Atrafi

2537

Accelerated vs. regular approval: Lessons learned from U.S. FDA oncology approvals.

Ihid Carneiro Leao

2540

Adverse events (AEs) in early phase cancer clinical trials.

Grace Mishkin

2542

Analysis of overall survival in patients with multiple primary malignancies.

Long H. Dang

e14520

AUCtox: A new method to evaluate the safety of anticancer drugs.

Vincent Launay-Vacher

2534

Enrolling patients in clinical trials: Advice from close family and friends.

François Eisinger

2533

Exaggeration of median progression-free survival (PFS) by blinded, independent, central review (BICR).

Andrew Stone

e14522

FACTS: Factors affecting combination trial success.

Channing Judith Paller

2544

Impact of flexible assessment schedules on treatment effect bias in pragmatic clinical trials.

Ariel B. Bourla

e14519

Implementing a comprehensive translational oncology platform: From molecular testing to actionability.

Zahi Ibrahim Mitri

e14521

Palbociclib (P) in patients (Pts) with pancreatic cancer (PC) and gallbladder or bile duct cancer (GBC) with CDKN2A alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.

Tareq Al Baghdadi

2532

Phase 0 (Ph0) and Window-of-Opportunity (WoO) trial quality and reporting.

Omar Farooq Khan

e14518

Physician experience and understanding of clinical trial adverse event attribution.

Jennifer Le-Rademacher

e14524

Prospective assessment of tumor biopsies as part of clinical trials: Patients’ (pts) perspectives.

Sunu Lazar Cyriac

2539

Single agent activity of U3-1402, a HER3-targeting antibody-drug conjugate, in breast cancer patients: Phase 1 dose escalation study.

Takahiro Kogawa

2512

Successes and challenges faced by tissue collection during trials by oncology translational sciences.

Martine P Roudier

2538

Systematic review of pediatric oncology phase I trials: Toxicity and outcomes in the era of targeted therapies.

Julia Wanda Cohen

2536

The rate of tumor growth during treatment accurately predicts the FDA gold standard of overall survival [OS] in a broad range of malignancies.

Julia Wilkerson

2545

Trends in oncology trials termination due to toxicity over a period of 16 years.

Laura Vidal

2535

Using real world data (RWD) analytics to drive operational efficiencies in basket trials.

Stelios Tzellos

e14517

Violations of the proportional hazards assumption in randomized phase III oncology clinical trials.

Rifaquat Rahman

2543